IE
TLOG

Israel Englander’s TetraLogic Pharmaceuticals Corporation TLOG Stock Holding History

Israel Englander’s Portfolio TLOG Stock Details TLOG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-58,897
Closed -$138K – 3948
2015
Q2 		$138K Buy
+58,897
New +$182K ﹤0.01% 3118

Other funds holding TLOG

CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
FWC
First Washington Corp Seattle, Washington $411M AUM 61.05% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Israel Englander's TLOG Position: Q3 2015 in Review

Israel Englander sold out of TetraLogic Pharmaceuticals Corporation (TLOG) in Q3 2015, closing a stake of 58,897 shares — an estimated $138K sold.

Israel Englander first reported a position in TLOG in Q2 2015 and held it in 1 quarter. The position peaked at $138K in Q2 2015. 29 funds tracked by Wall St. Rank hold TLOG as of Q3 2015.

  • Israel Englander reported no remaining TetraLogic Pharmaceuticals Corporation position as of Q3 2015 after selling out during the quarter.
  • Israel Englander sold 58,897 TetraLogic Pharmaceuticals Corporation shares in Q3 2015, an estimated $138K.
  • Israel Englander first reported a position in TetraLogic Pharmaceuticals Corporation in Q2 2015 and held it in 1 quarter.
  • Israel Englander's TetraLogic Pharmaceuticals Corporation position peaked at $138K in Q2 2015.
  • 29 funds tracked by Wall St. Rank held TetraLogic Pharmaceuticals Corporation as of Q3 2015.

Based on Millennium Management's 13F filing for Q3 2015, filed 16 Nov 2015.